Powered by: Motilal Oswal

News

Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd Revenue surged, Margins Improved Zydus Lifesciences Ltd. is one of India’s leading vertically integrated pharmaceutical companies, with presence across the value chain, from manufacturing of finished dosage forms to active pharmaceutical ingredients, animal healthcare products, and wellness products. ? In Q1FY24, the company’s consolidated revenue rose a significant 29.6% YoY to Rs. 5,140cr, primarily propelled by the US formulations business, which surged 57.4% YoY. ? EBITDA a...
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd
Source: Geojit Financial Services Ltd
24/08/2023 2:35:59 PM
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets Zydus Lifesciences is currently trading at Rs. 652.40, up by 7.75 points or 1.20% from its previous closing of Rs. 644.65 on the BSE. The scrip opened at Rs. 655.00 and has touched a high and low of Rs. 659.00 and Rs. 647.20 respectively. So far 18824 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets
Source: IANS
18/08/2023 10:23:30 AM
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal US quarterly revenue at historical high Work in progress to enhance product pipeline * Zydus Life Sciences (ZYDUSLIF) beat our earnings estimates in 1QFY24, aided by strong traction in exports to the US and EU, and healthy YoY growth in the domestic formulation (DF) and API segments. * We raise our FY24/FY25 earnings estimates by 8%/4% to factor in niche product launches in the US generics segment, seasonal impact on consumer healthcare brands, and DF segment growth in line with mark...
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal
Source: Motilal Oswal Financial Services
14/08/2023 2:58:42 PM
Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories Aug-03-2023   11:50 Hrs IST Zydus Lifesciences is currently trading at Rs. 648.25, up by 20.15 points or 3.21% from its previous closing of Rs. 628.10 on the BSE. The scrip opened at Rs. 620.05 and has touched a high and low of Rs. 651.30 and Rs. 620.05 respectively. So far 20489 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched...
Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories
Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories
Source: Accord Fintech
3/08/2023 12:10:42 PM
Zydus Lifesciences jumps on getting USFDA`s final nod for Plerixafor Injection Zydus Lifesciences is currently trading at Rs. 645.95, up by 23.50 points or 3.78% from its previous closing of Rs. 622.45 on the BSE. The scrip opened at Rs. 625.95 and has touched a high and low of Rs. 656.50 and Rs. 623.40 respectively. So far 84120 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 656.50 on 27-Jul-2023 and a 52 week low of Rs. 340.60 on 27-Jul-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences jumps on getting USFDA`s final nod for Plerixafor Injection
Zydus Lifesciences jumps on getting USFDA`s final nod for Plerixafor Injection
Source: Accord Fintech
27/07/2023 3:08:19 PM
Zydus Lifesciences rises on getting USFDA`s final nod for Oxcarbazepine Tablets Zydus Lifesciences rises on getting USFDA’s final nod for Oxcarbazepine Tablets Jul-05-2023   14:06 Hrs IST Zydus Lifesciences is currently trading at Rs. 582.10, up by 7.80 points or 1.36% from its previous closing of Rs. 574.30 on the BSE. The scrip opened at Rs. 574.85 and has touched a high and low of Rs. 583.25 and Rs. 573.90 respectively. So far 23649 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week ...
Zydus Lifesciences rises on getting USFDA`s final nod for Oxcarbazepine Tablets
Zydus Lifesciences rises on getting USFDA`s final nod for Oxcarbazepine Tablets
Source: Accord Fintech
5/07/2023 2:18:38 PM
Zydus Lifesciences inches up on getting tentative nod from USFDA for Palbociclib Tablets Zydus Lifesciences is currently trading at Rs. 584.20, up by 2.15 points or 0.37% from its previous closing of Rs. 582.05 on the BSE. The scrip opened at Rs. 586.05 and has touched a high and low of Rs. 587.45 and Rs. 581.30 respectively. So far 4495 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 588.85 on 28-Jun-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting tentative nod from USFDA for Palbociclib Tablets
Zydus Lifesciences inches up on getting tentative nod from USFDA for Palbociclib Tablets
Source: Accord Fintech
30/06/2023 10:07:06 AM
Zydus Lifesciences rises as its arm inks share purchase agreement to acquire stake in Mylab Zydus Lifesciences is currently trading at Rs. 559.20, up by 2.35 points or 0.42% from its previous closing of Rs. 556.85 on the BSE. The scrip opened at Rs. 560.00 and has touched a high and low of Rs. 563.50 and Rs. 558.10 respectively. So far 11529 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 564.50 on 21-Jun-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises as its arm inks share purchase agreement to acquire stake in Mylab
Zydus Lifesciences rises as its arm inks share purchase agreement to acquire stake in Mylab
Source: Accord Fintech
26/06/2023 11:50:43 AM
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets Zydus Lifesciences is currently trading at Rs. 556.30, up by 1.95 points or 0.35% from its previous closing of Rs. 554.35 on the BSE. The scrip opened at Rs. 556.00 and has touched a high and low of Rs. 558.00 and Rs. 553.80 respectively. So far 16064 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 562.15 on 19-Jun-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets
Source: Accord Fintech
20/06/2023 10:46:26 AM
Stock of the day: Buy Zydus Life Ltd For Target Rs.582 - Religare Broking ZYDUS LIFE * We are seeing consistent buying in select pharma counters and Zyduslife is trading in sync. * Inching gradually higher for the last nine months, after the consolidation range breakout. * Witnessed a fresh breakout from a consolidation range. Holding strongly above 20 EMA. * We recommend creating fresh longs in the mentioned range.   Buy Zydus Life Ltd  CMP 549.15; Range 546-549; SL 532; Target 582   To Read Complete Report &...
Stock of the day: Buy Zydus Life Ltd For Target Rs.582 - Religare Broking
Stock of the day: Buy Zydus Life Ltd For Target Rs.582 - Religare Broking
Source: Religare Broking Ltd
16/06/2023 10:21:59 AM
Zydus Lifesciences gains on getting USFDA`s final nod for Diclofenac Sodium and Misoprostol Delayed Release tablets Zydus Lifesciences is currently trading at Rs. 520.35, up by 2.65 points or 0.51% from its previous closing of Rs. 517.70 on the BSE. The scrip opened at Rs. 522.60 and has touched a high and low of Rs. 523.15 and Rs. 515.85 respectively. So far 29575 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 530.70 on 09-May-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final nod for Diclofenac Sodium and Misoprostol Delayed Release tablets
Zydus Lifesciences gains on getting USFDA`s final nod for Diclofenac Sodium and Misoprostol Delayed Release tablets
Source: Accord Fintech
14/06/2023 11:03:42 AM
Zydus Lifesciences jumps on getting final approval from USFDA for Varenicline Tablets Zydus Lifesciences is currently trading at Rs. 518.60, up by 8.65 points or 1.70% from its previous closing of Rs. 509.95 on the BSE. The scrip opened at Rs. 510.05 and has touched a high and low of Rs. 519.10 and Rs. 508.80 respectively. So far 27356 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 530.70 on 09-May-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences jumps on getting final approval from USFDA for Varenicline Tablets
Zydus Lifesciences jumps on getting final approval from USFDA for Varenicline Tablets
Source: Accord Fintech
13/06/2023 3:24:04 PM
Buy Zydus Lifesciences Ltd For Target Rs.570 - JM Financial Institutional Securities ZYDUSLIF reported a stellar quarter with 30%YoY revenue growth and ~21% EBITDAM (exRevlimid) driven by US business increased contribution from gRevlimid and gTrokendi. Reported PAT was impacted by goodwill impairment pertaining to Sentynl Therapeutics’ legacy business. ZYDUSLIF’s 4Q US sales at USD 275mn improved QoQ and the near-term launch pipeline remains strong with 3 trans-dermal launches from Moraiya, 2-REMS products, gTrokendi ramp-up, gVascepa and gRevlimid. These launches...
Buy Zydus Lifesciences Ltd For Target Rs.570 - JM Financial Institutional Securities
Buy Zydus Lifesciences Ltd For Target Rs.570 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
1/06/2023 3:33:57 PM
Zydus Lifesciences rises on getting final nod to manufacture, market Sucralfate Tablets Zydus Lifesciences is currently trading at Rs. 523.50, up by 3.60 points or 0.69 % from its previous closing of Rs. 519.90 on the BSE. The scrip opened at Rs. 523.50 and has touched a high and low of Rs. 523.50 and Rs. 523.50 respectively. So far 236 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 527.95 on 02-May-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nod to manufacture, market Sucralfate Tablets
Zydus Lifesciences rises on getting final nod to manufacture, market Sucralfate Tablets
Source: Accord Fintech
5/05/2023 10:21:38 AM
Zydus Lifesciences rises on getting final nod for Icosapent Ethyl Capsules from USFDA Zydus Lifesciences is currently trading at Rs. 522.75, up by 5.45 points or 1.05% from its previous closing of Rs. 517.30 on the BSE. The scrip opened at Rs. 517.30 and has touched a high and low of Rs. 524.35 and Rs. 516.00 respectively. So far 7326 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 524.35 on 24-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nod for Icosapent Ethyl Capsules from USFDA
Zydus Lifesciences rises on getting final nod for Icosapent Ethyl Capsules from USFDA
Source: Accord Fintech
24/04/2023 9:57:01 AM
Zydus Lifesciences inches up on getting USFDA`s final approval for Estradiol Transdermal System Zydus Lifesciences is currently trading at Rs. 517.10, up by 1.35 points or 0.26% from its previous closing of Rs. 515.75 on the BSE. The scrip opened at Rs. 519.70 and has touched a high and low of Rs. 519.70 and Rs. 514.50 respectively. So far 4781 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 519.70  on 19-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip ...
Zydus Lifesciences inches up on getting USFDA`s final approval for Estradiol Transdermal System
Zydus Lifesciences inches up on getting USFDA`s final approval for Estradiol Transdermal System
Source: Accord Fintech
19/04/2023 9:46:30 AM
Zydus Lifesciences rises on getting USFDA`s final approval for Isoproterenol Hydrochloride Injection Zydus Lifesciences is currently trading at Rs. 507.55, up by 3.90 points or 0.77% from its previous closing of Rs. 503.65 on the BSE. The scrip opened at Rs. 505.05 and has touched a high and low of Rs. 508.20 and Rs. 504.45 respectively. So far 2971 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 508.20 on 17-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting USFDA`s final approval for Isoproterenol Hydrochloride Injection
Zydus Lifesciences rises on getting USFDA`s final approval for Isoproterenol Hydrochloride Injection
Source: IANS
17/04/2023 9:41:54 AM
Zydus Lifesciences hits 52 week high on getting USFDA`s final approval for Tavaborole Topical Solution Zydus Lifesciences is currently trading at Rs. 503.50, up by 2.70 points or 0.54% from its previous closing of Rs. 500.80 on the BSE. The scrip opened at Rs. 500.05 and has touched a high and low of Rs. 503.50 and Rs. 498.50 respectively. So far 15706 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 503.50 on 12-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences hits 52 week high on getting USFDA`s final approval for Tavaborole Topical Solution
Zydus Lifesciences hits 52 week high on getting USFDA`s final approval for Tavaborole Topical Solution
Source: Accord Fintech
12/04/2023 11:32:38 AM
Zydus Lifesciences gains on getting USFDA`s final approval for Azithromycin Tablets Zydus Lifesciences is currently trading at Rs. 497.65, up by 1.15 points or 0.23% from its previous closing of Rs. 496.50 on the BSE. The scrip opened at Rs. 499.65 and has touched a high and low of Rs. 501.35 and Rs. 493.60 respectively. So far 39687 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 501.35 on 11-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Azithromycin Tablets
Zydus Lifesciences gains on getting USFDA`s final approval for Azithromycin Tablets
Source: Accord Fintech
11/04/2023 2:40:37 PM
Zydus gets US FDA nod for antibiotic drug Azithromycin Indian pharma company Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to manufacture and market antibiotic Azithromycin used to treat bacterial infections, the company announced on Monday. "Zydus Lifesciences Limited (including its subsidiaries/affiliates) has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Azithromycin tablets USP, 500 mg," the company said in a statement. Azithromy...
Zydus gets US FDA nod for antibiotic drug Azithromycin
Zydus gets US FDA nod for antibiotic drug Azithromycin
Source: IANS
10/04/2023 5:29:23 PM
Zydus Lifesciences surges on getting USFDA`s final approval for Carbidopa and Levodopa Tablets Zydus Lifesciences is currently trading at Rs. 495.50, up by 2.30 points or 0.47% from its previous closing of Rs. 493.20 on the BSE. The scrip opened at Rs. 491.05 and has touched a high and low of Rs. 497.00 and Rs. 491.05 respectively. So far 19989 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 497.00 on 06-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences surges on getting USFDA`s final approval for Carbidopa and Levodopa Tablets
Zydus Lifesciences surges on getting USFDA`s final approval for Carbidopa and Levodopa Tablets
Source: Accord Fintech
6/04/2023 2:56:42 PM
Zydus Lifesciences gains on getting USFDA`s final approval for Levothyroxine Sodium for Injection Zydus Lifesciences is currently trading at Rs 483.25, up by 0.95 points or 0.20% from its previous closing of Rs. 482.30 on the BSE. The scrip opened at Rs. 478.60 and has touched a high and low of Rs. 483.05 and Rs. 478.45 respectively. So far 10146 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting USFDA`s final approval for Levothyroxine Sodium for Injection
Zydus Lifesciences gains on getting USFDA`s final approval for Levothyroxine Sodium for Injection
Source: Accord Fintech
28/03/2023 11:10:58 AM
Key Stock Ideas: F&O, Zydus Lifesciences, TPG, - ARETE Securities NSE to roll back 6% transaction charges on equity and F&O trading from April 1: The board of National Stock Exchange (NSE) on March 24 stated that it has decided to rolled back the 6 percent increase in transaction charges on equity cash and derivatives segment, with effect from April 1.In January 2021, the charges were increased by 6 percent partly, to augment the investor corpus in view of certain market exigencies due to broker defaults. Zydus Recalls Over 55,000 Bottles Of Gener...
Key Stock Ideas: F&O, Zydus Lifesciences, TPG, - ARETE Securities
Key Stock Ideas: F&O, Zydus Lifesciences, TPG, - ARETE Securities
Source: ARETE Securities Ltd
27/03/2023 9:53:57 AM
Zydus Lifesciences gains on getting USFDA`s final approval for Doxepin Hydrochloride Capsules Zydus Lifesciences is currently trading at Rs. 483.15, up by 0.80 points or 0.17% from its previous closing of Rs. 482.35 on the BSE. The scrip opened at Rs. 480.35 and has touched a high and low of Rs. 483.40 and Rs. 478.65 respectively. So far 11881 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Doxepin Hydrochloride Capsules
Zydus Lifesciences gains on getting USFDA`s final approval for Doxepin Hydrochloride Capsules
Source: Accord Fintech
24/03/2023 12:21:18 PM
Zydus Lifesciences surges after its arm gets USFDA`s approval for Tofacitinib Tablets Zydus Lifesciences is currently trading at Rs. 483.20, up by 4.65 points or 0.97% from its previous closing of Rs. 478.55 on the BSE. The scrip opened at Rs. 478.60 and has touched a high and low of Rs. 484.50 and Rs. 478.20 respectively. So far 32866 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges after its arm gets USFDA`s approval for Tofacitinib Tablets
Zydus Lifesciences surges after its arm gets USFDA`s approval for Tofacitinib Tablets
Source: Accord Fintech
23/03/2023 4:39:30 PM
Zydus Lifesciences trades higher on getting orphan drug designation for ZYIL1 in treatment of patients with CAPS Zydus Lifesciences is currently trading at Rs. 478.75, up by 2.90 points or 0.61% from its previous closing of Rs. 475.85 on the BSE. The scrip opened at Rs. 474.00 and has touched a high and low of Rs. 479.00 and Rs. 473.95 respectively. So far 7403 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences trades higher on getting orphan drug designation for ZYIL1 in treatment of patients with CAPS
Zydus Lifesciences trades higher on getting orphan drug designation for ZYIL1 in treatment of patients with CAPS
Source: Accord Fintech
21/03/2023 12:46:07 PM
Zydus Lifesciences rises on getting USFDA's final nod for Erythromycin Tablets Zydus Lifesciences is currently trading at Rs. 472.70, up by 3.75 points or 0.80% from its previous closing of Rs. 468.95 on the BSE. The scrip opened at Rs. 468.00 and has touched a high and low of Rs. 473.70 and Rs. 465.80 respectively. So far 22582 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises on getting USFDA's final nod for Erythromycin Tablets
Zydus Lifesciences rises on getting USFDA's final nod for Erythromycin Tablets
Source: Accord Fintech
10/03/2023 11:03:36 AM
Zydus Lifesciences inches up on getting USFDA`s final approval for Lenalidomide Capsules Zydus Lifesciences is currently trading at Rs. 477.80, up by 1.80 points or 0.38% from its previous closing of Rs. 476.00 on the BSE. The scrip opened at Rs. 474.05 and has touched a high and low of Rs. 478.25 and Rs. 473.05 respectively. So far 3309 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting USFDA`s final approval for Lenalidomide Capsules
Zydus Lifesciences inches up on getting USFDA`s final approval for Lenalidomide Capsules
Source: Accord Fintech
8/03/2023 10:12:46 AM
Zydus Lifesciences trades higher on getting USFDAs approval for Apixaban Tablets Zydus Lifesciences is currently trading at Rs. 469.30, up by 3.75 points or 0.81% from its previous closing of Rs. 465.55 on the BSE. The scrip opened at Rs. 469.95 and has touched a high and low of Rs. 472.00 and Rs. 463.35 respectively. So far 6591 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences trades higher on getting USFDAs approval for Apixaban Tablets
Zydus Lifesciences trades higher on getting USFDAs approval for Apixaban Tablets
Source: Accord Fintech
1/03/2023 10:43:23 AM
Zydus Lifesciences rises as its arm gets approval to market Levomilnacipran Extended-Release Capsules Zydus Lifesciences is currently trading at Rs. 442.10, up by 0.85 points or 0.19% from its previous closing of Rs. 441.25 on the BSE. The scrip opened at Rs. 441.10 and has touched a high and low of Rs. 444.10 and Rs. 440.40 respectively. So far 4616 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 458.60 on 10-Jan-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises as its arm gets approval to market Levomilnacipran Extended-Release Capsules
Zydus Lifesciences rises as its arm gets approval to market Levomilnacipran Extended-Release Capsules
Source: Accord Fintech
16/01/2023 10:21:35 AM
Zydus Lifesciences rises as its arm gets USFDA`s final approval to market Brexpiprazole Tablets Zydus Lifesciences is currently trading at Rs. 454.30, up by 2.15 points or 0.48% from its previous closing of Rs. 452.15 on the BSE. The scrip opened at Rs. 452.90 and has touched a high and low of Rs. 457.00 and Rs. 447.50 respectively. So far 17014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 458.60 on 10-Jan-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises as its arm gets USFDA`s final approval to market Brexpiprazole Tablets
Zydus Lifesciences rises as its arm gets USFDA`s final approval to market Brexpiprazole Tablets
Source: IANS
12/01/2023 11:19:06 AM
Hold Zydus Lifesciences Ltd For Target Rs. 448 - ICICI Securities Moraiya cleared; Revlimid launched Zydus Lifesciences (Zydus) reported Q2FY23 performance is broadly in line with our estimates. Revenue grew 7.3% YoY to Rs40.0bn (I-Sec: Rs40.0bn) on the back of India and US markets. US sales was up 5.9% QoQ to US$214mn led by new launches including Revlimid offsetting the base price erosion. Consumer business reported healthy growth of 12.0% YoY driven by demand for its key products. Adjusted EBITDA margin contracted 450bps YoY (+140bps QoQ) to 19.9%. Ad...
Hold Zydus Lifesciences Ltd For Target Rs. 448 - ICICI Securities
Hold Zydus Lifesciences Ltd For Target Rs. 448 - ICICI Securities
Source: ICICI Securities
29/12/2022 12:56:33 PM
Zydus Lifesciences inches up as its arm gets final approval from USFDA for Selexipag Tablets Zydus Lifesciences is currently trading at Rs. 423.85, up by 0.25 points or 0.06% from its previous closing of Rs. 423.60 on the BSE. The scrip opened at Rs. 423.60 and has touched a high and low of Rs. 425.30 and Rs. 419.55 respectively. So far 4111 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up as its arm gets final approval from USFDA for Selexipag Tablets
Zydus Lifesciences inches up as its arm gets final approval from USFDA for Selexipag Tablets
Source: Accord Fintech
23/12/2022 10:06:22 AM
Zydus Lifesciences surges on getting final approval from USFDA for Estradiol Transdermal System Zydus Lifesciences is currently trading at Rs. 413.95, up by 2.65 points or 0.64% from its previous closing of Rs. 411.30 on the BSE. The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 415.45 and Rs. 408.80 respectively. So far 43481 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on getting final approval from USFDA for Estradiol Transdermal System
Zydus Lifesciences surges on getting final approval from USFDA for Estradiol Transdermal System
Source: Accord Fintech
2/12/2022 3:33:45 PM
Netrual Zydus LifeSciences Ltd For Target Rs.410 - Motilal Oswal India and US drives while Consumer Wellness and API drag earnings Product innovation a work-in-progress * ZYDUSLIF delivered a better-than-expected 2QFY23 performance, led by a superior product mix and controlled R&D spends. It continues to work on its innovation-led product pipeline as well as on complex generics to improve the growth in earnings going forward. * We reduced our FY23 earnings estimate by 3% to factor a moderation in profitability of Zydus Wellness, but increase o...
Netrual Zydus LifeSciences Ltd For Target Rs.410 - Motilal Oswal
Netrual Zydus LifeSciences Ltd For Target Rs.410 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
1/12/2022 3:39:19 PM
Zydus Lifesciences inches up on getting final approval to market Topiramate Extended-Release Capsules Zydus Lifesciences is currently trading at Rs. 410.85, up by 1.40 points or 0.34% from its previous closing of Rs. 409.45 on the BSE. The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 414.80 and Rs. 410.85 respectively. So far 3267 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting final approval to market Topiramate Extended-Release Capsules
Zydus Lifesciences inches up on getting final approval to market Topiramate Extended-Release Capsules
Source: Accord Fintech
1/12/2022 11:47:05 AM
Zydus Lifesciences inches up as its arm receives USFDA`s approval for Levothyroxine Sodium for Injection Zydus Lifesciences is currently trading at Rs. 402.65, up by 0.85 points or 0.21% from its previous closing of Rs. 401.80 on the BSE. The scrip opened at Rs. 402.10 and has touched a high and low of Rs. 404.80 and Rs. 402.10 respectively. So far 1015 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up as its arm receives USFDA`s approval for Levothyroxine Sodium for Injection
Zydus Lifesciences inches up as its arm receives USFDA`s approval for Levothyroxine Sodium for Injection
Source: Accord Fintech
28/11/2022 10:36:28 AM
India's Zydus Lifesciences Q2 profit plunges on rising costs Zydus Lifesciences on Friday reported an 82.6% slump in second-quarter profit hit by rising expenses, sending its shares down 1.5%. Consolidated profit for the three months ended Sept. 30 was 5.23 billion Indian rupees ($64.69 million), compared with 30.02 billion rupees a year ago, the company said in an exchange filing. Analysts on average had expected a profit of 5.52 bln rupees, according to Refinitiv IBES data. The Ahmedabad-based company's total expenses climbed 15.3% to 35...
India's Zydus Lifesciences Q2 profit plunges on rising costs
India's Zydus Lifesciences Q2 profit plunges on rising costs
Source: Reuters
11/11/2022 3:49:30 PM
Zydus Lifesciences gains on getting EIR for formulations manufacturing facility in Moraiya from USFDA Zydus Lifesciences is currently trading at Rs. 444.15, up by 4.35 points or 0.99% from its previous closing of Rs. 439.80 on the BSE. The scrip opened at Rs. 445.00 and has touched a high and low of Rs. 447.95 and Rs. 443.15 respectively. So far 6559 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 510.00 on 09-Nov-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting EIR for formulations manufacturing facility in Moraiya from USFDA
Zydus Lifesciences gains on getting EIR for formulations manufacturing facility in Moraiya from USFDA
Source: Accord Fintech
7/11/2022 9:36:36 AM
Zydus Lifesciences shines on getting final approval from USFDA for Acetaminophen injection Zydus Lifesciences is currently trading at Rs. 437.25, up by 7.75 points or 1.80% from its previous closing of Rs. 429.50 on the BSE. The scrip opened at Rs. 430.00 and has touched a high and low of Rs. 439.85 and Rs. 430.00 respectively. So far 689 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 511.90 on 29-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences shines on getting final approval from USFDA for Acetaminophen injection
Zydus Lifesciences shines on getting final approval from USFDA for Acetaminophen injection
Source: Accord Fintech
31/10/2022 10:05:00 AM
Zydus Lifesciences inches up on getting final approval from USFDA for Ketorolac Tromethamine Tablets Zydus Lifesciences is currently trading at Rs. 413.20, up by 0.05 points or 0.01% from its previous closing of Rs. 413.15 on the BSE. The scrip opened at Rs. 414.50 and has touched a high and low of Rs. 415.00 and Rs. 411.65 respectively. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 514.70 on 27-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood at Rs. 419.30 and Rs. 408.55 respectively. The ...
Zydus Lifesciences inches up on getting final approval from USFDA for Ketorolac Tromethamine Tablets
Zydus Lifesciences inches up on getting final approval from USFDA for Ketorolac Tromethamine Tablets
Source: Accord Fintech
25/10/2022 12:05:55 PM
Diwali 2022 : Technical picks By Anand Rathi Share and Stock Brokers BUY ARVIND FASHIONS LTD Scrip : ARVINDFASN; Sentiment: BULLISH; Entry : 310-290; Stop Loss: 230; Target :1 400; Target 2 : 440 *In the calendar year of 2021; ARVINDFASN rallied more than 150% in a matter of just 3 months (From 135 it went above 360 mark). Then after it corrected 61.8% of the entire move and has been consolidating. *At this juncture; it is again on the verge of fresh breakout and that indicates a continuation of the pr...
Diwali 2022 : Technical picks By Anand Rathi Share and Stock Brokers
Diwali 2022 : Technical picks By Anand Rathi Share and Stock Brokers
Source: Anand Rathi Share and Stock Brokers
18/10/2022 4:34:37 PM
Zydus Lifesciences jumps after its arm receives tentative approval from USFDA for Roflumilast Tablets Zydus Lifesciences is currently trading at Rs. 416.30, up by 4.90 points or 1.19% from its previous closing of Rs. 411.40 on the BSE. The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 416.90 and Rs. 409.00 respectively. So far 9982 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 545.00 on 18-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences jumps after its arm receives tentative approval from USFDA for Roflumilast Tablets
Zydus Lifesciences jumps after its arm receives tentative approval from USFDA for Roflumilast Tablets
Source: Accord Fintech
17/10/2022 12:28:34 PM
Zydus Lifesciences gains on getting final nod from USFDA for Brivaracetam Tablets Zydus Lifesciences is currently trading at Rs. 423.00, up by 3.00 points or 0.71% from its previous closing of Rs. 420.00 on the BSE. The scrip opened at Rs. 419.15 and has touched a high and low of Rs. 424.30 and Rs. 419.15 respectively. So far 36044 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 566.65 on 05-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting final nod from USFDA for Brivaracetam Tablets
Zydus Lifesciences gains on getting final nod from USFDA for Brivaracetam Tablets
Source: Accord Fintech
6/10/2022 10:09:17 AM
Key Stock News: Maruti Suzuki, JSW Cement, fintech, Nykaa, Zee Entertainment, Zydus Lifesciences - ARETE Securities Maruti Suzuki India vehicle production rises two-fold to 177k units in Sep Maruti Suzuki India on Monday reported an over two-fold rise in its vehicle production at 1,77,468 units in September 2022. The company had produced a total of 81,278 units in the same month last year. "The shortage of electronic components had a minor impact on the production of vehicles during the month," Maruti Suzuki India said in a regulatory filing. JSW Cement secures Rs 400 cr as sustainability-l...
Key Stock News: Maruti Suzuki, JSW Cement, fintech, Nykaa, Zee Entertainment, Zydus Lifesciences - ARETE Securities
Key Stock News: Maruti Suzuki, JSW Cement, fintech, Nykaa, Zee Entertainment, Zydus Lifesciences - ARETE Securities
Source: ARETE Securities Ltd
4/10/2022 9:34:38 AM
Zydus Lifesciences surges as its arm gets nod to market Mirabegron Extended-Release Tablets Zydus Lifesciences is currently trading at Rs. 394.50, up by 7.80 points or 2.02% from its previous closing of Rs. 386.70 on the BSE. The scrip opened at Rs. 386.05 and has touched a high and low of Rs. 394.65 and Rs. 386.05 respectively. So far 15053 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges as its arm gets nod to market Mirabegron Extended-Release Tablets
Zydus Lifesciences surges as its arm gets nod to market Mirabegron Extended-Release Tablets
Source: Accord Fintech
3/10/2022 10:34:01 AM
Zydus Lifesciences moves up on launching Lenalidomide Capsules in US Zydus Lifesciences is currently trading at Rs. 371.00, up by 11.30 points or 3.14% from its previous closing of Rs. 359.70 on the BSE. The scrip opened at Rs. 359.35 and has touched a high and low of Rs. 370.40 and Rs. 359.35 respectively. So far 23797 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences moves up on launching Lenalidomide Capsules in US
Zydus Lifesciences moves up on launching Lenalidomide Capsules in US
Source: Accord Fintech
20/09/2022 3:24:59 PM
Zydus Lifesciences gains on getting gets final approval from USFDA for Lenalidomide Capsules Zydus Lifesciences is currently trading at Rs. 376.90, up by 0.35 points or 0.09% from its previous closing of Rs. 376.55 on the BSE. The scrip opened at Rs. 376.65 and has touched a high and low of Rs. 379.25 and Rs. 374.40 respectively. So far 21775 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting gets final approval from USFDA for Lenalidomide Capsules
Zydus Lifesciences gains on getting gets final approval from USFDA for Lenalidomide Capsules
Source: Accord Fintech
13/09/2022 4:03:20 PM